C12N 15/86
Viral vectors
C12N15/86 (Viral vectors) appears on 8,014 US grants and 15,707 published applications in this corpus.
Search patents in C12N- Granted patents
- 8,014
- Published applications
- 15,707
- Assignees
- 3,939
- Inventors
- 22,728
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1983 | 2 | 0 |
| 1984 | 1 | 0 |
| 1985 | 0 | 0 |
| 1986 | 4 | 0 |
| 1987 | 2 | 0 |
| 1988 | 3 | 0 |
| 1989 | 7 | 0 |
| 1990 | 9 | 0 |
| 1991 | 17 | 0 |
| 1992 | 27 | 0 |
| 1993 | 42 | 0 |
| 1994 | 37 | 0 |
| 1995 | 33 | 0 |
| 1996 | 60 | 0 |
| 1997 | 128 | 0 |
| 1998 | 188 | 0 |
| 1999 | 185 | 0 |
| 2000 | 176 | 0 |
| 2001 | 200 | 57 |
| 2002 | 198 | 335 |
| 2003 | 183 | 452 |
| 2004 | 167 | 377 |
| 2005 | 124 | 367 |
| 2006 | 176 | 347 |
| 2007 | 154 | 265 |
| 2008 | 132 | 274 |
| 2009 | 144 | 280 |
| 2010 | 157 | 303 |
| 2011 | 133 | 278 |
| 2012 | 166 | 280 |
| 2013 | 166 | 267 |
| 2014 | 221 | 320 |
| 2015 | 208 | 302 |
| 2016 | 219 | 364 |
| 2017 | 230 | 438 |
| 2018 | 256 | 515 |
| 2019 | 297 | 768 |
| 2020 | 359 | 923 |
| 2021 | 406 | 1070 |
| 2022 | 473 | 1316 |
| 2023 | 524 | 1415 |
| 2024 | 535 | 1605 |
| 2025 | 690 | 1631 |
| 2026 | 575 | 1158 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Methods and materials for ameliorating creatine deficiency disorders6 Oct 2026US 12,751,995 B2The Regents of the University of California
- BCMA chimeric antigen receptors6 Oct 2026US 12,752,006 B2Regeneron Pharmaceuticals, Inc.
- Engineered meganucleases having specificity for a recognition sequence in the hydroxyacid oxidase 1 gene6 Oct 2026US 12,752,019 B2Precision BioSciences, Inc.
- Microdystrophin nucleic acid gene therapy constructs and uses thereof6 Oct 2026US 12,752,020 B2REGENXBIO Inc.
- Methods of manufacturing microdystrophin gene therapy constructs6 Oct 2026US 12,752,021 B2REGENXBIO Inc.
- Targeted Immune Cell Therapy Utilizing TRAIL and TNF Mediated Apoptosis8 Oct 2026US 2026/0306542 A1Northeastern University
- Treating a type i interferon upregulation or aberrant il-33 upregulation disease or condition with polyomavirus8 Oct 2026US 2026/0306609 A1The General Hospital Corporation
- Systems and Methods for Delivery of Viral Antigens8 Oct 2026US 2026/0306610 A1Veergen Inc.
- Capsids and methods of targeting neurons8 Oct 2026US 2026/0306661 A1Capsigen Inc.
- Molecular-genetic strategy for the reactivation of juvenile plasticity in targeted adult neural circuits8 Oct 2026US 2026/0306662 A1The Regents of the University of California
Most cited
By later US patents
- AAV transduction vectors618US 5,139,941 AUniversity of Florida Research Foundation, Inc. · 1992
- In vivo introduction and expression of foreign genetic material in epithelial cells586US 4,980,286 AWhitehead Institute for Biomedical Research · 1990
- Engineering and optimization of systems, methods and compositions for sequence manipulation with functional domains568US 8,993,233 B2Massachusetts Institute of Technology · 2015
- Engineering and optimization of improved systems, methods and enzyme compositions for sequence manipulation489US 8,865,406 B2Massachusetts Institute of Technology · 2014
- Adeno-associated virus as eukaryotic expression vector481US 4,797,368 AThe United States of America as represented by the Department of Health and Human Services · 1989